Mechanisms of HOX Protein Mediated Transformation

HOX蛋白介导的转化机制

• 批准号: 7471408
• 负责人: Jay L. Hess
• 金额: $ 22.94万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-15 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7471408
• 关键词: Acute; Acute leukemia; Affect; Affinity; Animal Model; Binding; Binding Sites; Bioinformatics; Cell Line; Cells; Complex; DNA Sequence Rearrangement; Defective spinal cord development; Disease; Dysmyelopoietic Syndromes; Genes; Goals; Growth; HOX protein; HOXA9 gene; Hematopoietic; Homeobox Genes; Knowledge; Lymphoid; MEIS1 gene; Maps; Mediating; Molecular; Myeloid Leukemia; Oncogenes; Pathway interactions; Protein Isoforms; Protein Overexpression; Proteins; Regulatory Element; Risk; Role; Specificity; Work; base; cell transformation; cofactor; human MEIS1 protein; insight; knock-down; leukemia; leukemogenesis; novel therapeutics; therapeutic target; tool; tumor

DESCRIPTION (provided by applicant): Overexpression of the homeobox gene HOXA9 is emerging as an important mechanism of deregulated growth in both myelodysplasia and acute lymphoid and myeloid leukemias. HOXA9 is expressed at high levels in acute leukemias with MLL rearrangements, in myelodysplastic disorders and in high risk AMI. By itself, HOXA9 is a weak oncogene. However, in tumors, HOXA9 is almost always coexpressed with MEIS1, a HOX cofactor. Furthermore, HOXA9 and MEIS1 strongly cooperate to produce leukemia in animal models. Understanding the molecular basis for this cooperativity is pivotal for developing targeted therapy. Two general mechanisms of cooperativity are possible. One involves direct physical interaction between HOXA9 and MEIS1. This could result in altered HOXA9 localization or stability or change the affinity or specificity of HOXA9 in binding to transcriptional targets. Alternatively, HOXA9 and MEIS1 may regulate distinct pathways that cooperate in leukemogenesis. Progress toward this goal has been hampered by lack of knowledge of the proteins associated with HOXA9 and lack of insight into downstream targets of HOXA9 and MEIS1. In this proposal, two strategies would be pursued for identifying proteins associated with HOXA9 in cells transformed by HOXA9. We will determine if more than one HOXA9 complex exists in leukemia cells and what the role of the abundantly expressed HOXA9T isoform is on transformation. We will determine if MEIS1 overexpression affects the localization and composition of HOXA9 complexes and if reducing HOXA9 or MEIS1 expression blocks transformation. Cell lines with conditional forms of HOXA9 and MEIS1 or knock down will be used to identify direct and indirect targets of HOXA9. Using bioinformatics tools, we will identify and characterize regulatory elements responsive to HOXA9 in hematopoietic cells. Overall, this work will provide mechanistic insights into HOXA9 mediated transformation and is likely to uncover promising new therapeutic targets in myelodysplasia and leukemia.

描述（由申请人提供）：同源异型盒基因HOXA 9的过表达正在成为骨髓增生异常和急性淋巴细胞和骨髓性白血病中生长失调的重要机制。HOXA 9在伴有MLL重排的急性白血病、骨髓增生异常疾病和高危AMI中以高水平表达。HOXA 9本身是一种弱致癌基因。然而，在肿瘤中，HOXA 9几乎总是与HOX辅因子MEIS 1共表达。此外，HOXA 9和MEIS 1强烈合作，在动物模型中产生白血病。了解这种协同作用的分子基础是发展靶向治疗的关键。有两种普遍的协同机制是可能的。其中一个涉及HOXA 9和MEIS 1之间的直接物理相互作用。这可能导致改变的HOXA 9定位或稳定性，或改变HOXA 9与转录靶标结合的亲和力或特异性。或者，HOXA 9和MEIS 1可能调节在白血病发生中协同作用的不同途径。由于缺乏对HOXA 9相关蛋白的了解，以及缺乏对HOXA 9和MEIS 1下游靶点的了解，这一目标的进展受到阻碍。在该提议中，将采用两种策略来鉴定由HOXA 9转化的细胞中与HOXA 9相关的蛋白质。我们将确定在白血病细胞中是否存在一个以上的HOXA 9复合物，以及大量表达的HOXA 9T同种型在转化中的作用。我们将确定MEIS 1过表达是否影响HOXA 9复合物的定位和组成，以及减少HOXA 9或MEIS 1表达是否会阻断转化。具有条件形式的HOXA 9和MEIS 1或敲低的细胞系将用于鉴定HOXA 9的直接和间接靶标。使用生物信息学工具，我们将确定和表征造血细胞中响应HOXA 9的调控元件。总的来说，这项工作将为HOXA 9介导的转化提供机制上的见解，并可能发现骨髓增生异常和白血病有希望的新治疗靶点。